Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreetta C, Ferro A, Zambelli A, Gori S, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Guarneri V, et al. Among authors: frassoldati a. Eur J Cancer. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2. Eur J Cancer. 2021. PMID: 34225066 Free article. Clinical Trial.
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A, Buzzi P. Cocconi G, et al. Among authors: frassoldati a. Am J Clin Oncol. 1999 Dec;22(6):593-600. doi: 10.1097/00000421-199912000-00010. Am J Clin Oncol. 1999. PMID: 10597744 Clinical Trial.
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Bian AR, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M. Colozza M, et al. Among authors: frassoldati a. Eur J Cancer. 2002 Nov;38(17):2279-88. doi: 10.1016/s0959-8049(02)00452-5. Eur J Cancer. 2002. PMID: 12441265 Clinical Trial.
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research. Colozza M, et al. Among authors: frassoldati a. Clin Breast Cancer. 2005 Aug;6(3):253-9. doi: 10.3816/cbc.2005.n.028. Clin Breast Cancer. 2005. PMID: 16137437
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: frassoldati a. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Frassoldati A, Guarneri V, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF. Frassoldati A, et al. Clin Breast Cancer. 2008 Feb;8(1):97-100. doi: 10.3816/CBC.2008.n.010. Clin Breast Cancer. 2008. PMID: 18501066 Free article. Clinical Trial.
160 results